The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics-Reference-Cited by-同舟云学术

The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics

Published:2012-06-15 Issue:2 Volume:89 Page:165-176
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Casademunt Elisabeth¹,Martinelle Kristina²,Jernberg Mats²,Winge Stefan²,Tiemeyer Maya¹,Biesert Lothar³,Knaub Sigurd⁴,Walter Olaf⁴,Schröder Carola¹

Affiliation:

1. Octapharma Munich Germany

2. Octapharma Stockholm Sweden

3. Octapharma Frankfurt Germany

4. Octapharma Lachen Switzerland

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1600-0609.2012.01804.x

Reference53 articles.

1. The hemophilias: progress and problems;Mannucci PM;Semin Hematol,1999

2. BrowerC ThompsonA.Hemophilia A.2010March 25. Available from:http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=hemo-a. Last accessed April 30 2010.

3. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiplex, multimodal mapping of variant effects in secreted proteins;2024-04-01

2. A review of fetal cell lines used during drug development: Focus on COVID-19 vaccines, transplant medications, and biologics;American Journal of Health-System Pharmacy;2024-02-13

3. Simoctocog alfa (Nuwiq^®) in children: early steps in life’s journey for people with severe hemophilia A;Therapeutic Advances in Hematology;2024-01

4. Biologic from mammalian and non-mammalian cell lines;Advanced Biologic Drugs and Manufacturing Process;2024

5. Optimizing Excipient Properties to Prevent Aggregation in Biopharmaceutical Formulations;Journal of Chemical Information and Modeling;2023-12-19